Nalaganje...
Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years
BACKGROUND: Rivastigmine, a butyl- and acetylcholinesterase inhibitor, is approved for symptomatic treatment of Alzheimer's disease (AD). Data supporting the safety and efficacy of second-generation cholinesterase inhibitors, such as rivastigmine, are available for treatment up to 1 year, with...
Shranjeno v:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2005
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC548267/ https://ncbi.nlm.nih.gov/pubmed/15659242 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2318-5-3 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|